|
Where does the name Fermiscan come from?
The life and work of physicist Enrico Fermi (1901-1954) was a significant inspiration for the founders of Fermiscan Pty Limited; a contribution recognised in the company name. His attitude towards scientific discovery reflects the importance of maintaining an open mind to achieve scientific breakthroughs.
Enrico Fermi made a major contribution to advancing the science of high-energy particle physics. To him this was the most exciting area of physics.
Fermi did most of his early work in Italy, and in 1938 received the Nobel Prize for "his discovery of new radioactive elements produced by neutron irradiation, and for the discovery of nuclear reactions brought about by slow neutrons." After leaving Europe, Fermi continued his research at the University of Chicago, concentrating on nuclear and elementary particle physics.
He was heavily involved in the design of the synchrocyclotron at the University of Chicago, which was at the time, one of the most powerful 'atom smashers' in the world. Like all visionaries, Fermi was able to predict future developments in his field. Fermi accurately predicted the synchrotrons of today, speculating that giant accelerators would be built in the future. Apparently, he even dreamed of a particle accelerator that would be located at the equator and encircle the globe!
 |
Fig.1 'There are two possible outcomes. If the result confirms the hypothesis, then you have made a measurement. If the result is contrary to the hypothesis, then you have made a discovery!'
- Enrico Fermi (1901 - 1954). |
In what countries does Fermiscan have patent protection?
Fermiscan has patents granted in USA, Australia, New Zealand and Europe with patents pending in other major international markets.
Are diseases other than breast cancer covered under Fermiscan's family of patents?
Fermiscan's family of patents includes detection of other pathological states, in particular prostate cancer, colon cancer and Alzheimer's disease, with other patent applications being lodged.
Back to top
|